In contrast to MYC, potent MYCN suppression was observed in every neuroblastoma cell line tested that expressed MYCN. Importantly, dose-dependent inhibition of MYCN expression was also observed in the CHP-212 xenograft model, indicating that N-Myc driven pathways are similarly affected in vitro and in vivo. The gene discussed is MYC; the disease is neuroblastoma.